UBS Maintains Buy on Rapport Therapeutics, Lowers Price Target to $64
Guggenheim Maintains Buy on Rapport Therapeutics, Lowers Price Target to $66
Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $47
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
Rapport Therapeutics Q3 EPS $(0.84) Beats $(1.19) Estimate
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement
Rapport Therapeutics Closes Underwritten Public Offerings Of 9,761,905 Shares At $21.00 Per Share
Rapport Therapeutics Prices Stock, Convertible Notes Offerings; Private Placement; Shares Fall
Rapport Therapeutics stock tumbles on $350M capital raise
Rapport Therapeutics Sinks 22% on Discounted $350 Million Stock and Convertible Note Raise
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
Rapport Therapeutics Prices Separate Offerings Of ~$175M Of Stock At $21.00/Share, Warrants To Purchase Up To ~$25M Of Stock At $20.999 Per Pre-Funded Warrant, And $150M Of 2.25% Convertible Senior Notes Due 2032
Rapport Therapeutics (RAPP) Shares Sink 20% After Hours
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
Rapp Therapeutics Files For Offering Of Common Stock; Size Not Disclosed
Rapport Therapeutics Commences Separate Underwritten Public Offerings Of $200M Of Shares And $150M Aggregate Principal Amount Of Convertible Senior Notes Due 2032
Rapport Therapeutics’ RAP-219 Hits Phase II Goals in Bipolar Mania Trial
Rapport Therapeutics (RAPP) Could Be 62% Below Fair Value Following Phase 2 Mania Data
Rapport Therapeutics (RAPP) Stock Gets Fair Value Boost After RAP 219 Bipolar Mania Data
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.